MX2009006598A - Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl). - Google Patents

Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).

Info

Publication number
MX2009006598A
MX2009006598A MX2009006598A MX2009006598A MX2009006598A MX 2009006598 A MX2009006598 A MX 2009006598A MX 2009006598 A MX2009006598 A MX 2009006598A MX 2009006598 A MX2009006598 A MX 2009006598A MX 2009006598 A MX2009006598 A MX 2009006598A
Authority
MX
Mexico
Prior art keywords
cptl
sulfonamide derivatives
palmitoyl transferase
carnitine palmitoyl
liver carnitine
Prior art date
Application number
MX2009006598A
Other languages
English (en)
Inventor
Patrizio Mattei
Odile Chomienne
Ulrike Obst Sander
Simona M Ceccarelli
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009006598A publication Critical patent/MX2009006598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a nuevos derivados de sulfonamida de fórmula (I) (ver fórmula I) en donde R1, R2, R3, X e Y tienen los significados definidos en la descripción y en las reivindicaciones, así como a las sales y ésteres fisiológicamente aceptables de los mismos. Estos compuestos inhiben la L-CPT1 y pueden utilizarse como medicamentos.
MX2009006598A 2006-12-21 2007-12-11 Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl). MX2009006598A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06126920 2006-12-21
PCT/EP2007/063696 WO2008074692A1 (en) 2006-12-21 2007-12-11 Sulfonamide derivatives as liver carnitine palmitoyl transferase (l-cptl )

Publications (1)

Publication Number Publication Date
MX2009006598A true MX2009006598A (es) 2009-07-24

Family

ID=39273549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006598A MX2009006598A (es) 2006-12-21 2007-12-11 Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).

Country Status (17)

Country Link
US (1) US7799933B2 (es)
EP (1) EP2097373B1 (es)
JP (1) JP5089707B2 (es)
KR (1) KR101139211B1 (es)
CN (1) CN101583597B (es)
AR (1) AR064459A1 (es)
AT (1) ATE477240T1 (es)
AU (1) AU2007336364B2 (es)
BR (1) BRPI0720524A2 (es)
CA (1) CA2672761A1 (es)
CL (1) CL2007003697A1 (es)
DE (1) DE602007008467D1 (es)
ES (1) ES2348270T3 (es)
MX (1) MX2009006598A (es)
PE (1) PE20081485A1 (es)
TW (1) TW200833324A (es)
WO (1) WO2008074692A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017827A1 (en) * 2008-08-14 2010-02-18 European Molecular Biology Laboratory 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012064744A2 (en) * 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX367341B (es) 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
MX363350B (es) * 2012-05-08 2019-03-20 Merck Sharp & Dohme COMPUESTOS DE SULFONA BICÍCLICA PARA LA INHIBICIÓN DE LA ACTIVIDAD RORgamma Y EL TRATAMIENTO DE ENFERMEDADES.
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
AU2016219183B2 (en) 2015-02-11 2020-06-11 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
WO2017075185A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
JP2018535958A (ja) 2015-10-27 2018-12-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用
JP2020524718A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
CN110511182B (zh) * 2019-09-03 2023-01-17 上海昕凯医药科技有限公司 一种连续流反应合成7-硝基-1,2,3,4-四氢喹啉的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
CA2608837C (en) 2005-06-06 2011-08-02 F. Hoffmann-La Roche Ag Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l-cpt1) inhibitors
EP1926711B1 (en) * 2005-09-15 2012-11-07 F. Hoffmann-La Roche AG Novel heterobicyclic derivatives useful as inhibitors of liver carnitine palmitoyl transferase

Also Published As

Publication number Publication date
TW200833324A (en) 2008-08-16
JP2010513376A (ja) 2010-04-30
DE602007008467D1 (de) 2010-09-23
PE20081485A1 (es) 2008-10-18
BRPI0720524A2 (pt) 2014-01-07
US20080153805A1 (en) 2008-06-26
CN101583597A (zh) 2009-11-18
ATE477240T1 (de) 2010-08-15
WO2008074692A1 (en) 2008-06-26
CN101583597B (zh) 2012-07-11
EP2097373B1 (en) 2010-08-11
CL2007003697A1 (es) 2008-07-04
CA2672761A1 (en) 2008-06-26
JP5089707B2 (ja) 2012-12-05
AU2007336364A1 (en) 2008-06-26
AU2007336364B2 (en) 2012-08-02
AR064459A1 (es) 2009-04-01
KR101139211B1 (ko) 2012-04-26
US7799933B2 (en) 2010-09-21
EP2097373A1 (en) 2009-09-09
ES2348270T3 (es) 2010-12-02
KR20090080567A (ko) 2009-07-24

Similar Documents

Publication Publication Date Title
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
IL187409A0 (en) Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l- cpt1) inhibitors
TW200745032A (en) Novel heterobicyclic derivatives
TW200738655A (en) Novel bicyclic sulfonamide derivatives
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
MX2010005824A (es) Derivados de aminotiazol.
MY138941A (en) Aryl-pyridine derivatives
UA94052C2 (uk) Похідні піридазину
MX2009010218A (es) Derivados de aza-piridopirimidinona.
TW200740758A (en) Benzoquinazoline derivatives
TW200740764A (en) Pyrazolone derivatives
WO2006114401A3 (en) Novel cyclic amines
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
TW200616976A (en) Pyrimidine derivatives
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
MX2010003224A (es) Derivados de biaril sulfonamida.
IN2012DN03337A (es)
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
UA109037C2 (uk) Триазолопіридини
WO2009021868A3 (en) Novel piperazine amide derivatives
UA102310C2 (ru) Гетероциклические сульфонамиды, их применение и фармацевтические композиции
MX2009003169A (es) Derivados de sulfonamida.

Legal Events

Date Code Title Description
FG Grant or registration